Retatrutide
Details
Retatrutide is a once-weekly subcutaneous triple agonist of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon receptors. It is being developed by Eli Lilly for chronic weight management and obesity-related complications. The addition of glucagon receptor agonism increases energy expenditure and hepatic fat oxidation alongside the appetite-suppressing and insulinotropic effects of GIP and GLP-1 agonism. In the phase 3 TRIUMPH-1 trial, retatrutide produced mean weight reductions of 17.6–25.0% at 80 weeks with the treatment-regimen estimand and up to 28.3% with the efficacy estimand, the largest weight loss reported for any obesity pharmacotherapy to date. (sources/Retatrutide-Obesity-NEJM-2026, rating: very high)
Key Facts
Pharmacology
- Triple receptor agonist: GIP, GLP-1 and glucagon receptors.
- Once-weekly subcutaneous injection; fixed dose-escalation schedule to 4 mg, 9 mg or 12 mg in TRIUMPH-1.
- Up to two permanent dose reductions were permitted for gastrointestinal adverse events during the first 20 weeks, and at any time for inadequate food or fluid intake, BMI ≤22 or excessive weight loss.
- Phase 2 trial (n=338) showed −24.2% weight at 48 weeks with 12 mg and improvements in waist circumference, blood pressure, glycated haemoglobin and lipids.
- A phase 2a substudy showed a substantial reduction in liver fat, the largest reported for an incretin-based therapy at the time. (sources/masld-nejm-2025, rating: high)
TRIUMPH-1 — Phase 3 Obesity Trial
- Population: 2,339 adults with obesity and without diabetes; mean age 48.4 years; 65.6% women; mean BMI 40.0; 77.4% with BMI ≥35; 131 sites in 11 countries.
- Design: 80 weeks of treatment plus 4 weeks of follow-up, with a 24-week extension to week 104 in approximately 500 participants; 4 mg, 9 mg, 12 mg or placebo.
- Primary weight outcome (treatment-regimen estimand): −17.6%, −23.7% and −25.0% versus −3.9% with placebo; differences −13.7, −19.8 and −21.0 percentage points (P<0.001).
- Efficacy estimand: −19.0%, −25.9% and −28.3% versus +2.2%.
- Weight reduction ≥35%: 5.7–21.1% versus 0.2% with placebo; ≥30% in more than one third of participants.
- BMI <30 achieved in 40.1–57.1%; BMI <25 in 12.0–26.3%; waist-to-height ratio <0.5 in 10.1–20.4%.
- Extension to week 104: −18.9% with placebo switched to retatrutide, −25.7% with 4 mg, −28.7% with 9 mg and −29.9% with 12 mg (treatment-regimen estimand).
Knee Osteoarthritis Basket
- 574 participants with moderate or severe knee osteoarthritis and radiographic evidence.
- WOMAC pain change at week 80 (hybrid-treatment estimand): −3.2, −3.5 and −3.6 points versus −1.9 with placebo; differences for 9 and 12 mg −1.6 and −1.8 points (P<0.001).
- Intention-to-treat estimand: −3.4, −3.9 and −4.1 versus −2.5; differences −1.4 and −1.6 points (P<0.001).
Obstructive Sleep Apnea Basket
- 243 participants with apnea–hypopnea index ≥15, with or without positive airway pressure therapy.
- Apnea–hypopnea index change at week 80 (hybrid-treatment estimand): −22.9, −34.3 and −31.7 events per hour versus −9.9; differences for 9 and 12 mg −24.4 and −21.9 (P<0.001).
- Intention-to-treat estimand: −22.8, −34.3 and −32.1 versus −9.6; differences −24.7 and −22.5 (P<0.001).
- The magnitude of reduction is comparable to or greater than that reported with tirzepatide in obesity-related obstructive sleep apnea.
Cardiometabolic Effects
- Waist circumference −15.7, −20.1 and −21.6 cm; systolic blood pressure −7.6, −9.8 and −10.4 mmHg.
- Triglycerides −30.9%, −36.4% and −38.0%; non-HDL cholesterol −16.7%, −21.9% and −20.6%.
- Fasting insulin −43.1%, −51.9% and −54.5%; high-sensitivity C-reactive protein −57.7%, −61.6% and −62.6%.
- Among participants with prediabetes at baseline, reversion to normoglycaemia occurred in 89.4–93.2% versus 54.2% with placebo.
- Physical-function and psychosocial quality-of-life scores improved significantly.
Safety
- Gastrointestinal adverse events were the most common: nausea 28.6–42.4%, diarrhoea 25.2–34.1%, constipation 23.8–26.1%, vomiting 10.6–25.3%.
- Treatment discontinuation for adverse events: 4.1%, 6.5% and 11.1% versus 4.6%; discontinuation for perceived excessive weight loss: 0.3%, 1.0% and 5.3% versus 0%.
- Serious adverse events: 7.7%, 7.7% and 10.5% versus 5.5%.
- Dysesthesia (skin burning sensation and related events) 5.1%, 12.3% and 12.5% versus 0.9%; injection-site reactions 5.5%, 8.9% and 12.2% versus 3.8%; hypotension 2.7%, 5.3% and 8.8% versus 0.9%.
- Pulse rate increased, peaking at week 20 at the 9- and 12-mg doses and declining thereafter.
- No medullary thyroid cancer or drug-induced liver injury; urinary tract infections 7.5–8.7% versus 5.3%, predominantly in women.
- Adjudication-confirmed pancreatitis occurred in 1, 3 and 4 participants versus 2; numbers are too small for conclusions.
- Adjudication-confirmed major adverse cardiovascular events occurred in 1, 5 and 3 participants versus 1; the trial was not powered for cardiovascular safety.
Comparison with Other Incretin-Based Therapies
| Agent | Receptors | Weight loss in obesity trials | Key cardiovascular data |
|---|---|---|---|
| Semaglutide 2.4 mg | GLP-1 | ~15–17% at 68 weeks | SELECT MACE HR 0.80; STEP-HFpEF KCCQ +7.8 |
| Tirzepatide 15 mg | GIP + GLP-1 | ~20–22% at 72 weeks | SUMMIT HFpEF composite HR 0.62 |
| Retatrutide 12 mg | GIP + GLP-1 + glucagon | ~25% at 80 weeks; up to 28.3% efficacy estimand | No cardiovascular outcome trial yet; TRIUMPH-Outcomes ongoing |
- The cross-trial comparison is indirect: populations, trial durations, estimands and background care differ, and no head-to-head trial exists.
- Retatrutide's weight loss approaches that of bariatric surgery, which raises the question of whether obesity should be treated to a defined target rather than to a maximum tolerated dose.
- The 2025 ACC concise clinical guidance frames semaglutide, tirzepatide and liraglutide as nutrient-stimulated hormone therapies and does not require a trial of lifestyle intervention before pharmacotherapy; retatrutide would be expected to enter that framework if approved. (sources/weight-mx-acc-2025, rating: very high)
Pipeline
- TRIUMPH-Outcomes (NCT06383390) is evaluating cardiovascular and kidney outcomes.
- Phase 2a data support a role in metabolic dysfunction-associated steatotic liver disease, with substantial liver-fat reduction.
- The TRIUMPH programme includes separate registrational trials in obesity, obstructive sleep apnea and knee osteoarthritis.
Contradictions / Open Questions
- Cardiovascular safety is unproven. TRIUMPH-1 was not powered for major adverse cardiovascular events, and the numerical distribution of events (1, 5 and 3 versus 1) is too small to interpret. Until TRIUMPH-Outcomes reports, retatrutide has no outcome data comparable to SELECT or SUMMIT.
- Glucagon agonism is a double-edged mechanism. It increases energy expenditure and hepatic fat oxidation, but also raises heart rate and can worsen glycaemia through hepatic glucose output. The net clinical effect of the glucagon component is not fully characterised.
- Dysesthesia is a retatrutide-specific signal. Skin burning and related events occurred in up to 12.5% of participants, far more than with GLP-1 or dual GIP/GLP-1 agonists. The mechanism and reversibility are unknown.
- The maximum-tolerated-dose paradigm may be wrong for this drug. Dose reductions for excessive weight loss were common at 12 mg, and the authors suggest aiming for the minimum effective dose needed to reach a treatment target. No trial has compared a treat-to-target strategy with maximum-tolerated dosing.
- The trial has no active comparator. Greater attrition in the placebo group may reflect access to other obesity medications, and the absence of an active comparator limits indirect comparisons with semaglutide and tirzepatide.
- Generalizability to milder obesity is limited. Only 2% of participants had a baseline BMI <30, so the results apply mainly to moderate-to-severe obesity.
- The extension phase is small and short. The 104-week data come from approximately 500 participants who entered an extension, not from the full trial population.
- The effect on lean mass is unclear. Weight loss of this magnitude may include substantial lean mass; the trial did not report body-composition endpoints, and the risk of sarcopenic obesity is relevant, particularly in older adults.
Connections
- Related to concepts/GLP-1-Receptor-Agonists — the incretin class and its cardiovascular outcome trials
- Related to concepts/NuSH-Therapies — the nutrient-stimulated hormone therapy framework
- Related to entities/Tirzepatide — the dual GIP/GLP-1 comparator
- Related to entities/Semaglutide — the GLP-1 comparator
- Related to entities/Obesity — the primary indication
- Related to entities/Obstructive-Sleep-Apnea — one of the basket populations
- Related to entities/MASLD — the liver phenotype and phase 2a data
- Related to concepts/HFpEF-Management — obesity-HFpEF as a downstream phenotype
- Related to concepts/Visceral-Adiposity — the mechanistic target